Existing Treatments Offer Hope for Managing Severe Muscular Dystrophy Symptoms

Recent research from the Hospital for Special Surgery indicates that current therapies may play a role in alleviating some symptoms associated with the severe form of muscular dystrophy, particularly Duchenne muscular dystrophy (DMD). Published in the Proceedings of the National Academy of Sciences, the study sheds light on new mechanisms that sustain chronic muscle inflammation, a hallmark of DMD progression. The disease stems from a mutation in the dystrophin gene, resulting in the loss of a vital protein that maintains muscle cell integrity. As a consequence, muscles undergo damage, leading to persistent inflammation, scarring, muscle weakness, and ultimately, premature death,

primarily affecting boys. Despite the severity, existing treatments that target inflammation could be harnessed to improve patient outcomes.

The research focused on immune cells called monocytes and macrophages, which infiltrate muscle tissue and contribute to damaging inflammation and scarring. It was found that blocking monocyte recruitment temporarily reduces macrophage accumulation and muscle scarring, improving muscle function. However, this benefit is transient, highlighting the need to identify additional factors driving inflammation.

Using advanced technologies like single-cell RNA sequencing, scientists discovered that fibro/adipogenic progenitors (FAPs), a type of stem cell in muscle tissue, produce growth factors known as colony-stimulating factor (CSF-1). CSF-1 stimulates resident macrophages to proliferate and contribute to chronic inflammation. This insight suggests that effective management of DMD may require a combination approach, targeting both macrophage infiltration and resident macrophage expansion.

Next steps include exploring safety and efficacy of combination therapies utilizing existing drugs: one that reduces macrophage infiltration and another that inhibits CSF-1. Such strategies could modify the diseased muscle environment to enhance the success of gene and cell therapies, which currently face limitations.

The findings emphasize that tackling inflammation through targeted drugs could significantly improve muscle health and slow disease progression in DMD patients, potentially extending life expectancy and quality of life.

For more information: source.